[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. furnished a 6-K reporting that, on October 29, 2025, it issued a press release titled “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger.” The press release is included as Exhibit 99.1.

The filing indicates the company is highlighting ongoing support for the ITOL-102 diabetes program in the context of its merger with Kadimastem. The report is administrative in nature and provides the press release as an exhibit for investors’ reference.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 7)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On October 29, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger.” A copy of this press release is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: October 29, 2025	By:	/s/ Alexander C. Zwyer
		Name:	Alexander C. Zwyer
		Title:	Chief Executive Officer

2

FAQ

What did NLSP announce in this 6-K filing?

The company furnished a press release as Exhibit 99.1 highlighting continued BIRD Foundation support for the ITOL-102 diabetes program following its merger with Kadimastem.

When was the NLSP press release issued?

It was issued on October 29, 2025.

What is included as Exhibit 99.1 for NLSP?

A press release titled “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger.”

What form did NLSP file?

A Form 6-K Report of Foreign Private Issuer.

Who signed the NLSP filing?

It was signed by Alexander C. Zwyer, Chief Executive Officer.

What is NLS Pharmaceutics’ listed address?

The Circle 6, 8058 Zurich, Switzerland.